MEFIB指数与MAST评分在代谢功能障碍相关脂肪性肝病肝功能失代偿评估中的个体参与者数据荟萃分析
本研究为个体参与者数据的纵向回顾性荟萃分析,纳入美国、日本和土耳其共454例代谢功能障碍相关脂肪性肝病患者,评估MEFIB指数与MAST评分对肝功能失代偿的预测价值。中位随访4.2年间,MEFIB指数阳性(HR=49.22)和MAST评分阳性(HR=3.86)均为肝功能失代偿的显著预测因子,且MEFIB指数预测效能优于MAST评分。
要点
- MEFIB指数阳性(MRE≥3.3 kPa且FIB-4≥1.6)与肝功能失代偿风险显著相关,HR=49.22。
- MAST评分>0.242与肝功能失代偿风险显著相关,HR=3.86。
- MEFIB指数预测肝功能失代偿的c-statistic为0.89,优于MAST评分的0.81。
核心结论
- 基于MRI的生物标志物与血液检测组合,MEFIB指数和MAST评分均可预测MASLD患者肝功能失代偿风险。
研究设计与样本
- 纵向回顾性分析,纳入美国、日本和土耳其接受基线MRE和MRI-PDFF检查并随访肝功能失代偿的受试者。
- 个体参与者数据荟萃分析共纳入454例患者(58%为女性),平均(±SD)年龄56.0(±13.5)岁。
- 采用Cox比例风险分析评估MEFIB指数与MAST评分和复合主要结局(肝功能失代偿)的关联。
- 复合主要结局定义为腹水、肝性脑病和需要治疗的静脉曲张。
主要发现
- MEFIB指数(MRE≥3.3 kPa且FIB-4≥1.6)阳性者占样本34%,MAST评分(>0.242)阳性者占9%。
- 基线时23例患者符合肝功能失代偿标准;在297例有纵向数据的患者中,中位(IQR)随访4.2(5.0)年,25例发生肝功能失代偿。
- MEFIB指数阳性是肝功能失代偿的显著预测因子,HR=49.22(95%CI:6.23-388.64,p<0.001)。
- MAST评分阳性是肝功能失代偿的显著预测因子,HR=3.86(95%CI:1.46-10.17,p<0.001)。
- MEFIB指数预测肝功能失代偿的c-statistic为0.89(SE=0.02),MAST评分为0.81(SE=0.03),两者差异有统计学意义(p<0.0001)。
关键数值与推荐
- MEFIB指数阳性定义为MRE≥3.3 kPa且FIB-4≥1.6。
- MAST评分阳性定义为>0.242。
- 肝功能失代偿复合结局定义为腹水、肝性脑病和需要治疗的静脉曲张。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited data regarding the longitudinal association between MEFIB-Index (MRE combined with FIB-4) versus MAST-Score (MRI-aspartate aminotransferase) and hepatic decompensation. AIM: To examine the longitudinal association between MEFIB-Index versus MAST-Score in predicting hepatic decompensation in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). METHODS: This was a longitudinal, retrospective analysis of subjects from United States, Japan, and Turkey who underwent a baseline MRE and MRI-PDFF and were followed for hepatic decompensation. Cox-proportional hazard analyses were used to assess the association between MEFIB-Index versus MAST-Score with a composite primary outcome (hepatic decompensation) defined as ascites, hepatic encephalopathy, and varices needing treatment. RESULTS: This meta-analysis of individual participants (IPDMA) included 454 patients (58% women) with a mean (±SD) age of 56.0 (±13.5) years. The MEFIB-Index (MRE ≥3.3 kPa + FIB 4 ≥1.6) and MAST-Score (>0.242) were positive for 34% and 9% of the sample, respectively. At baseline, 23 patients met criteria for hepatic decompensation. Among 297 patients with available longitudinal data with a median (IQR) of 4.2 (5.0) years of follow-up, 25 incident cases met criteria for hepatic decompensation. A positive MEFIB-Index [HR = 49.22 (95% CI: 6.23-388.64, p < 0.001)] and a positive MAST-Score [HR = 3.86 (95% CI: 1.46-10.17, p < 0.001)] were statistically significant predictors of the incident hepatic decompensation. MEFIB-Index (c-statistic: 0.89, standard error (SE) = 0.02) was statistically superior to the MAST-Score (c-statistic: 0.81, SE = 0.03) (p < 0.0001) in predicting hepatic decompensation. CONCLUSION: A combination of MRI-based biomarker and blood tests, MEFIB-Index and MAST-Score can predict the risk of hepatic decompensation in patients with MASLD.
引用
- Noureddin N, Ajmera V, Bergstrom J, et al. MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analyses. Aliment Pharmacol Ther. 2023. PMID: 37694993. doi:10.1111/apt.17707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。